大规模新冠病毒核酸筛查的生物安全问题  

Biosafety issues of large-scale SARS-CoV-2 nucleic acid screening

作　　者：甘雁妃[1] 钟礼信 戴奇山[1] 聂玉强[1] 王轶[1] GAN Yanfei;ZHONG Lixin;DAI Qishan;NIE Yuqiang;WANG Yi(Guangzhou First People's Hospital,Guangzhou 510180,China)

机构地区：[1]广州市第一人民医院,广州510180

出　　处：《广州医药》2022年第1期101-104,共4页Guangzhou Medical Journal

摘　　要：目的本文旨在对全流程的生物安全管理问题进行梳理,为未来出现的大规模核酸筛查提供参考。方法我们参考技术规范及其他医疗机构的实践总结,结合自身实际经验,梳理了核酸采集场所、个人防护、标本采集转运检测流程共3个方面的生物安全管理需注意的问题及解决措施。严格要求采样队伍按标准要求执行,以达到保质保量完成筛查任务的目的。结果新冠核酸筛查期间我院共外派采集标本361841人次。标本零污染零丢失,未发生一例生物安全事件,圆满完成采样任务。结论大规模新冠核酸筛查是查清疫情源头、抑制疫情蔓延的重要手段。为了保证全流程的生物安全,应做好充足准备,严格落实各项生物安全措施。Objective This article aims to sort out the problems in the whole process of biosafety management and provide reference for large-scale nucleic acid screening in the future.Methods We refer to the technical guidelines and the practice of other medical institutions,combined with our practical experience,summarized the problems and solutions needing attention in biosafety management in three aspects:nucleic acid sampling place,personal protection and the process from sample collection to detection.The sampling team was strictly required to implement the standard requirements,so as to complete the screening task with quality and quantity.Results A total of 361841 samples were collected during SARS-CoV-2 nucleic acid screening.No samples were contaminated or lost,and no biosafety accident occurred.The sampling task were successfully completed.Conclusion Large-scale SARS-CoV-2 nucleic acid screening is an important method to find out the source of the epidemic and curb the spread of the SARS-CoV-2 pandemic.In order to ensure the biosafety of the whole process,sufficient preparations should be made and biosafety measures should be strictly implemented.

关 键 词：新型冠状病毒 核酸筛查 生物安全管理 

分 类 号：R440[医药卫生—诊断学]